Ongoing HTAs by the Galician Scientific and Technical Advice Unit

24

May 2021

The Galician Scientific and Technical Advice Unit in Spain (AVALIA-T) systematically evaluates healthcare technologies and provides decision-makers with critically reviewed information about their efficacy, safety, and effectiveness.

As of May 24, 2021, the AVALIA-T is working on the following assessments related to medical procedures or technologies:

  • Biomonitoring of Hexachlorocyclohexane metabolites as exposure markers and their utility in exposed individuals monitoring;
  • Endovascular treatment of varicose veins: radiofrequency ablation and cyanoacrylate venous adhesive;
  • Effectiveness and safety of epiduroscopy in the treatment of failed back surgery syndrome and lumbar spinal stenosis;
  • Bronchial thermoplasty for severe acute asthma;
  • Ventricular assist devices (VADs) in pediatric patients with an indication for permanent destination therapy;
  • Monitoring study protocol: Left ventricular assist devices in destination therapy;
  • Oral home enteral nutrition in cancer patients requiring modification of the oral diet by mucositis even if there is no malnutrition;
  • Home enteral nutrition in elderly patients with severe protein-energy malnutrition after hip fracture. Systematic review;
  • Oral home enteral nutrition in the cancer patient in active treatment and with severe malnutrition that does not reverse through the single intake of food for ordinary consumption;
  • Organizational models for the provision of palliative care;
  • Update on the clinical effectiveness of neonatal screening for congenital metabolic errors: maple syrup urine disease, isovaleric acidemia, and homocystinuria;
  • Protocol for proper use of tests and results of 25-hydroxy-vitamin D;
  • Clinical Practice Guide on palliative care for adults in the last days;
  • Methodological development line: Development of the PriTec application;
  • Methodological development line: Plan for the detection of emerging technologies;
  • Comparative results of the different screening strategies for trisomies 21, 13, and 18: adaptation of the EUnetHTA report.

The details of the ongoing assessments can be found here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).

The latest related news

24

Mar 2022

The HTA body of the Tuscany Regional Healthcare issues two types of documents: HTA forms and motivational forms. With a regional decree 2472 of February 10, 2022, Tuscany Regional Healthcare has published assessments of five medical devices of various therapeutic areas, such as cardiovascular and peripheral vascular areas.

Read more

18

Mar 2022

On February 22, 2022, a repository of innovative acts outside the nomenclature of biology and anatomopathology (RIHN) and a Supplementary list of IVD tests were published. Minor changes were introduced in the 2022 RIHN list.

Read more

17

Mar 2022

On February 21, 2022, it was announced by the Ministry of Health that the public consultation regarding the Draft Order amending the Common Package of Benefits of the National Health System (SNS) was open. The amendments and clarifications are related to the fields of in-vitro diagnostics, ENT, pulmonary and airways, e-health, neurology, dental care, radiology, and enteral nutrition.

Read more

15

Mar 2022

The Belgian Health Care Knowledge Center (KCE) initiated a study aimed at defining a clear and transparent procedure for the evaluation of digital health technologies in Belgium.

Read more

11

Mar 2022

On February 07, 2022, the Dental and Pharmaceutical Benefits Agency has announced the withdrawal of the assessments of the PhysioMem PM 100 and CardioMem CM 100 XT and the finalization of the assessments of the Zenicor ECG, Coala Heart Monitor Pro, and KardiaMobile. For the conducted assessments, it was outlined that the portable devices provide more limited information than standard ECG measurements; therefore, it was mainly estimated for atrial fibrillation.

Read more